| P50 | author | Stephen E. Harding | Q7609121 |
| | Paul S. Morgan | Q51692894 |
| | Gary G Adams | Q56855577 |
| | Richard B Gillis | Q56855578 |
| | Naomi Chayen | Q61994023 |
| | Andrew Meal | Q125292957 |
| P2093 | author name string | Frank Coffey | |
| | Qushmua Alzahrani | |
| | Arthur J Rowe | |
| | Samil Kok | |
| | Shahwar I Jiwani | |
| P2860 | cites work | Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec | Q27683621 |
| | Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation Modeling | Q27860847 |
| | Disulfide Linkage Characterization of Disulfide Bond-Containing Proteins and Peptides by Reducing Electrochemistry and Mass Spectrometry. | Q30382778 |
| | Evaluation of the information content of sedimentation equilibrium data in self-interacting systems | Q33622585 |
| | COVOL: an interactive program for evaluating second virial coefficients from the triaxial shape or dimensions of rigid macromolecules. | Q34170398 |
| | Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. | Q34583341 |
| | Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) | Q36426912 |
| | A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes | Q36449523 |
| | Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments | Q36597980 |
| | Novel insulin analogues and its mitogenic potential | Q36616563 |
| | Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes | Q36964626 |
| | MultiSig: a new high-precision approach to the analysis of complex biomolecular systems | Q37300072 |
| | Basal insulin analogues in the management of diabetes mellitus: What progress have we made? | Q38136581 |
| | The osmotic second virial coefficient for protein self-interaction: Use and misuse to describe thermodynamic nonideality | Q38582064 |
| | Proliferative and signaling activities of insulin analogues in endometrial cancer cells | Q38908011 |
| | Rational steering of insulin binding specificity by intra-chain chemical crosslinking | Q41960756 |
| | The concentration-dependence of macromolecular parameters | Q41971526 |
| | Equivalent radii and ratios of radii from solution properties as indicators of macromolecular conformation, shape, and flexibility. | Q44004609 |
| | Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects | Q44495234 |
| | The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients | Q44631767 |
| | Rhombohedral insulin crystal transformation | Q45206559 |
| | Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. | Q47175820 |
| | Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles | Q47772554 |
| | Concentration dependence of translational diffusion coefficients for globular proteins. | Q51026292 |
| | Insulin analogues display atypical differentiative activities in skin keratinocytes. | Q53535262 |
| | Structure of Rhombohedral 2 Zinc Insulin Crystals | Q55872723 |
| | Equilibrium cluster formation in concentrated protein solutions and colloids | Q59063283 |
| | Structural relationships in the two-zinc insulin hexamer | Q66921732 |
| | Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use | Q73922459 |
| | Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis | Q81317578 |
| | Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes | Q84440683 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7287 | |
| P577 | publication date | 2017-08-04 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Glargine and degludec: Solution behaviour of higher dose synthetic insulins | |
| P478 | volume | 7 | |